The New England journal of medicine, 2020-04, Vol.382 (16), p.1520-1530
2020
Details
- Autor(en) / Beteiligte
- Titel
- Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia
- Ist Teil von
- The New England journal of medicine, 2020-04, Vol.382 (16), p.1520-1530
- Ort / Verlag
- United States: Massachusetts Medical Society
- Erscheinungsjahr
- 2020
- Link zum Volltext
- Quelle
- Alma/SFX Local Collection
- Beschreibungen/Notizen
- This phase 3 trial evaluated the safety and efficacy of inclisiran, a small interfering RNA that inhibits hepatic PCSK9 synthesis, in 482 adults with heterozygous familial hypercholesterolemia, who received subcutaneous injections of inclisiran or placebo on days 1, 90, 270, and 450. Changes in cholesterol were assessed up to day 540.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793eISSN: 1533-4406DOI: 10.1056/NEJMoa1913805Titel-ID: cdi_proquest_miscellaneous_2381628775
- Format
- –
- Schlagworte
- Apolipoproteins, Arteriosclerosis, Cardiovascular disease, Cardiovascular diseases, Cholesterol, Cholesterol, LDL, Confidence intervals, Control, Deoxyribonucleic acid, DNA, Dosage, Dosage and administration, Drug therapy, Genetic aspects, Genotypes, Health aspects, Health risk assessment, Heterozygosis, Heterozygosity, Hypercholesterolemia, Immunoglobulins, Injections, Hypodermic, Kexin, Low density lipoprotein, Monoclonal antibodies, Patient outcomes, Proprotein convertases, siRNA, Software, Statins, Subtilisin, Testing